Phase 4 N=92 Efficacy of High-dose Intravenous Immunoglobulin Therapy for Hyperbilirubinemia Due Rh Hemolytic Disease
Hyperbilirubinemia · Erythroblastosis, Fetal
Primary: Need of Exchange Transfusion — 6; 7 participants — p=0.765
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=30 Sirolimus for Autoimmune Disease of Blood Cells
Autoimmune Pancytopenia · Autoimmune Lymphoproliferative Syndrome (ALPS) · Evans Syndrome
Primary: Number of Participants With Grade 3 and 4 Toxicities of Administration of Oral Sirolimus — 1 participants
Phase 2 N=25 A Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia
Autoimmune Hemolytic Anemia
Primary: Percentage of Participants Attaining a Complete Response at Any Visit From Week 6 to Week 12 — 20.0; 40.0 percentage of participants
Phase 2 N=24 Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD)
Warm Autoimmune Hemolytic Anemia · Cold Agglutinin Disease
Primary: Number of Subjects With Treatment Emergent Adverse Events (TEAEs) Including by Severity — 5; 5; 7; 6 Participants
Phase 2 N=1 Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and AMD3100
Fanconi Anemia
Primary: Number of Participants Who Safely Received AMD3100 Used in Combination With Standard Dose G-CSF — 1 participants
N/A N=809 Is Iron Deficiency the Cause of Anemia Among Women in Cambodia?
Anemia · Iron Deficiency · Hemoglobin Disorder
Primary: Hemoglobin Levels at 12-weeks. Marginal Means (95% CI). — 123; 116; 121; 116 g/L — p=<0.05
Phase 3 N=6 High Dose Cyclophosphamide for Treatment of Scleroderma
Scleroderma
Primary: Improvement in the Modified Rodnan Skin Score. — 46.75 percent improvement from baseline
Phase 4 N=40 Inpatient Penicillin Allergy Delabeling Study
Penicillin Allergy · Penicillin Sensitivity · Penicillin Reaction
Primary: Number of Participants With Confirmed Allergy Status — 28; 6; 6 Participants
N/A N=60 Auto-antibodies Prevalence and CD1 Role in Gaucher Disease
Gaucher Disease
Primary: Number of Patients With GD Diagnosis Confirmed by : Enzyme Testing of acidβ-glucosidase Activity Activity <15% in Blood Leucocytes Completed When Necsssary by GB1…
Phase 2 N=5 Sirolimus Injections for Autoimmune Scleritis
Scleritis
Primary: Number of Participants Who Experience at Least 2-step Reduction or Reduction to Grade 0 of Scleral Inflammation in the Study Eye According to the National Eye Institute…
N/A N=34 Transient Elastography in Autoimmune Hepatitis
Liver Cirrhosis
Primary: Sensitivity and Specifity of Transient Elastography in Detection of Liver Cirrhosis — 0.83; 1.00; 1.00; 0.97 Probability
Phase 2 N=34 Eltrombopag for Moderate Aplastic Anemia
Moderate Aplastic Anemia · Unilineage Bone Marrow Failure Disorders
Primary: Proportion of Drug Responders — 17 Participants
Phase 2 N=11 Rituximab to Treat Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan Anemia
Anemia, Aplastic · Red-Cell Aplasia, Pure · Anemia, Diamond-Blackfan
Primary: Response to Rituximab — 0; 2; 9 participants
N/A N=23 Feasibility or Oral Lactoferrin to Prevent Iron Deficiency Anemia in Obese Pregnancy
Iron-deficiency · Pregnancy Anemia · Obesity
Primary: Recruitment Feasibility — 10 percentage eligible and enrolled
Phase 2 N=23 Horse ATG/CsA in Aplastic Anemia Patients Unresponsive to or With a Suboptimal Response to Rabbit ATG/CsA Treatment
Anemia, Aplastic · Anemia, Hypoplastic
Primary: Number of Participants With Complete Response at 3 Months. — 0 Participants